Entries by Organicell

Organicell’s “Advances of Exosome-Based Therapeutics in the Clinic” article featured on Bioinformant

“Organicell Regenerative Medicine is amongst the first groups of innovators to spearhead the use of naturally occurring extracellular vesicles as a next-generation therapeutic tool for inflammatory and chronic disease.” Learn more about Organicell’s “Advances of Exosome-Based Therapeutics in the Clinic” in our most recent published article on Bioinformant.  Read the full article

Organicell and Proxima CRO Set to Open Clinical Trial for Long Hauler COVID-19 Patients

Miami, FL Miami (February 8, 2022)—Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has secured its first site to carry out the Organicell Phase I/II Multicenter, Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Zofin™ Infused Intravenous (IV) in Patients Experiencing […]

Register Now for the 2nd Operationalize Expanded Access Programs Conference Happening February 15-17

Join Organicell along with leading Expanded Access Program thinkers sharing their expertise and knowledge towards bringing treatments to patients in need. Secure your spot by registering today: https://operationalize-eap.com/take-part/register/?utm_source=digital&utm_medium=social-post&utm_campaign=other-general-promotion&utm_content=linkedin/organicell-speaker/ev-23689

Organicell Regenerative Medicine, Inc. Provides Updates of Clinical Trial Activities

MIAMI, FL / ACCESSWIRE / December 29, 2021 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is pleased to provide its stockholders and the investment community with the following updates regarding its approved Investigational New Drug Applications (“IND”) and other clinical trial related activities surrounding Zofin™, its […]

Organicell Among Key Industry Experts Discussing the Impact of long-haul COVID on Drug Development in a Virtual Roundtable hosted by Parexel

“As progress is made in addressing the COVID-19 pandemic with vaccines and treatment pathways, reports about the long-term effects of the infection are building.” Pharmaceutical Executive in collaboration with Parexel organized a roundtable of experts from various stake-holder groups, including Organicell’s Chief Science Officer Dr. Mari Mitrani, to discuss the current research into long-haul COVID. Read […]

Proof-of-Concept Trial of an Amniotic Fluid-Derived Extracellular Vesicle Biologic for Treating High Risk Patients with Mild-to-Moderate Acute COVID-19 Infection

Organicell’s latest research publication is now available to read in Biomaterials and Biosystems Journal, “Proof-of-Concept Trial of an Amniotic Fluid-Derived Extracellular Vesicle Biologic for Treating High Risk Patients with Mild-to-Moderate Acute COVID-19 Infection”. 

We have dedicated this to our Primary Investigator who didn’t have the chance to see it published. Thank you Dr. Friedewald, your career has greatly impacted us and has left us inspired to continue your legacy.

Read the full publication here.

 

Organicell Announces Approval to Uplist Common Stock to OTCQB

Miami, FL (November 9, 2021) — Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that its application to uplist its common stock to the OTCQB Venture Market (the “OTCQB”) has been approved by OTC Markets Group, Inc.  Organicell’s common stock will commence trading on […]

FINRA Approves Marketplace Name Change to Organicell Regenerative Medicine, Inc. and Trading Symbol Change To “OCEL”

MIAMI, Nov. 5, 2021 /PRNewswire/ — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has received confirmation from the Financial Industry Regulatory Agency (“FINRA“) that the pending marketplace name change and trading symbol change request to Organicell Regenerative Medicine, Inc. and “OCEL” has been approved.  […]

Register Now for the 3rd Annual Exosome Based Therapeutic Development Summit

Register now for The 3rd Annual Exosome Based Therapeutic Development Summit digital event happening November 16-18. Join Organicell along with leading pharma, biotech, technology providers and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine, COVID-19 and beyond. Secure your spot by registering today: Register Now